Form 4: Vita Coco CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Vita Coco Company CEO Martin Roper executed planned sales of common stock totaling 40,000 shares across direct and family trust holdings in late September 2025.

Summary

• Martin Roper, Chief Executive Officer and Director of Vita Coco Company, Inc. (COCO), reported the sale of 40,000 shares of common stock.
• The sales occurred on September 22, 2025, and September 23, 2025, with 20,000 shares sold on each date.
• All transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Direct sales by Martin Roper totaled 10,000 shares at weighted average prices of $40.168 and $40.515.
• Indirect sales included 10,000 shares each from the Christopher G. Roper Exempt Family Trust, Peter S. Roper Exempt Family Trust, and Thomas L. Roper Exempt Family Trust, at weighted average prices ranging from $40.00 to $40.92.
• Following these transactions, Martin Roper directly beneficially owns 324,297 shares of common stock.
• Indirect beneficial ownership includes 258,806 shares by the Christopher G. Roper Exempt Family Trust, 257,915 shares by the Peter S. Roper Exempt Family Trust, 258,931 shares by the Thomas L. Roper Exempt Family Trust, and 61,200 shares by his spouse.
• Martin Roper also holds 1,099,460 non-qualified stock options with various exercise prices and vesting schedules, some fully vested and others vesting in annual installments through March 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can be viewed negatively, the execution under a Rule 10b5-1 plan indicates pre-scheduled transactions, which are generally considered less indicative of management's immediate outlook on the company's prospects compared to ad-hoc sales. This transparency mitigates potential negative interpretations.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, indicating pre-scheduled transactions and reducing concerns about opportunistic insider selling.

Negatives

• Insider selling, even if planned, can sometimes be perceived negatively by the market as it reduces management's direct equity stake.

Risks

• Potential for minor negative market sentiment if investors misinterpret the planned sales as a lack of confidence, despite the 10b5-1 plan.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report is specific to the individual's holdings and does not provide broader industry context or competitive analysis.

Stakeholder Impact

• Shareholders: May experience minor shifts in sentiment due to insider selling, though the 10b5-1 plan typically lessens concerns about management's confidence.

Key Dates

Recommendation

This Form 4 primarily reports routine, pre-scheduled insider stock sales under a 10b5-1 plan. Such transactions are generally not considered a strong signal for a buy or sell recommendation on their own, as they often relate to personal financial planning rather than a change in company outlook. Investors should consider broader company fundamentals and market conditions when making investment decisions.

Keywords

Vita Coco Company, COCO, Martin Roper, CEO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Equity Sales